MYC and diffuse large B-cell lymphoma: Clinical cohort analysis revealed that high expression of CDCA7 is significantly linked to shortened overall survival in DLBCL patients, and its co-occurrence with MYC rearrangement indicates a poorer response to rituximab therapy.